{
    "organizations": [],
    "uuid": "047c90dd56b2e6281b74ee64cd3b92c4f6383cf1",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-pain-therapeutics-resubmits-new-dr/brief-pain-therapeutics-resubmits-new-drug-application-for-remoxy-er-idUSFWN1Q30ZE",
    "ord_in_thread": 0,
    "title": "Pain Therapeutics Resubmits New Drug Application For Remoxy ER",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 13 (Reuters) - Pain Therapeutics Inc:\n* PAIN THERAPEUTICS RESUBMITS NEW DRUG APPLICATION FOR REMOXYÂ® ER, AN ABUSE-DETERRENT, EXTENDED-RELEASE DRUG CANDIDATE FOR THE TREATMENT OF CHRONIC PAIN\n* PAIN THERAPEUTICS INC - COMPANY EXPECTS A SIX-MONTH REVIEW CYCLE BY FDA FOR REMOXY NDA\n* PAIN THERAPEUTICS INC - EXPECTS TO BE NOTIFIED BY FDA OF A PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE WITHIN 60 DAYS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-13T21:23:00.000+02:00",
    "crawled": "2018-02-14T12:43:54.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "pain",
        "therapeutic",
        "inc",
        "pain",
        "therapeutic",
        "resubmits",
        "new",
        "drug",
        "application",
        "er",
        "drug",
        "candidate",
        "treatment",
        "chronic",
        "pain",
        "pain",
        "therapeutic",
        "inc",
        "company",
        "expects",
        "review",
        "cycle",
        "fda",
        "remoxy",
        "nda",
        "pain",
        "therapeutic",
        "inc",
        "expects",
        "notified",
        "fda",
        "prescription",
        "drug",
        "user",
        "fee",
        "act",
        "pdufa",
        "date",
        "within",
        "day",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}